First, most patients carrying MDS-R mutations harbored ASXL1 (40.6%) or RUNX1 (41.6%) mutations, and thus they would be included in the adverse-risk group defined by the 2017 ELN classification. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.